Overview

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

Status:
Active, not recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Phase:
Phase 3
Details
Lead Sponsor:
BioMarin Pharmaceutical
Treatments:
Natriuretic Peptide, C-Type